These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2414226)

  • 1. Prevention and treatment of cytomegalovirus infections with interferons and immune globulins.
    Meyers JD
    Infection; 1985; 13 Suppl 2():S211-8. PubMed ID: 2414226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of cytomegalovirus infections with interferons and immune globulins.
    Meyers JD
    Infection; 1984; 12(2):143-50. PubMed ID: 6203842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus (CMV) antibody in male homosexuals: a source for CMV immune globulin.
    Ikram H; Prince AM; Baker LN
    Vox Sang; 1983 Mar; 44(3):173-7. PubMed ID: 6301160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.
    Bowden RA; Sayers M; Flournoy N; Newton B; Banaji M; Thomas ED; Meyers JD
    N Engl J Med; 1986 Apr; 314(16):1006-10. PubMed ID: 3007984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytomegalovirus infection and acquired immunodeficiency syndrome].
    Farber NA; Zhdanov VM
    Vopr Virusol; 1986; 31(4):389-93. PubMed ID: 2429453
    [No Abstract]   [Full Text] [Related]  

  • 7. New developments in cytomegalovirus prevention and management.
    Snydman DR; Rubin RH; Werner BG
    Am J Kidney Dis; 1993 Feb; 21(2):217-28. PubMed ID: 8381578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion-transmitted cytomegalovirus infections: significance and control.
    Tegtmeier GE
    Vox Sang; 1986; 51 Suppl 1():22-30. PubMed ID: 3017003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives for the control of cytomegalovirus infections in bone marrow transplant recipients.
    Pollard RB; Merigan TC
    Transplant Proc; 1978 Mar; 10(1):241-5. PubMed ID: 205021
    [No Abstract]   [Full Text] [Related]  

  • 10. Human Cytomegalovirus Particles Treated with Specific Antibodies Induce Intrinsic and Adaptive but Not Innate Immune Responses.
    Wu Z; Qin R; Wang L; Bosso M; Scherer M; Stamminger T; Hotter D; Mertens T; Frascaroli G
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transplanted kidney as a source of cytomegalovirus infection.
    Ho M; Suwansirikul S; Dowling JN; Youngblood LA; Armstrong JA
    N Engl J Med; 1975 Nov; 293(22):1109-12. PubMed ID: 171567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cytomegalovirus infection after marrow transplantation.
    Meyers JD
    Rev Infect Dis; 1989; 11 Suppl 7():S1691-705. PubMed ID: 2557664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cytomegalovirus infection.
    Meyers JD
    Am J Med; 1988 Aug; 85(2A):102-6. PubMed ID: 2841853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].
    Gluckman E; McMazeron ; Keable H; Meletis J; Bombail D; Jolivet I; Huart JJ; Nebout T; Cavazzana M; De Castro H
    Nouv Rev Fr Hematol (1978); 1987; 29(1):17-21. PubMed ID: 3035485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
    Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
    Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients.
    Aulitzky WE; Tilg H; Niederwieser D; Hackl M; Meister B; Huber C
    J Infect Dis; 1988 Aug; 158(2):488-9. PubMed ID: 2841384
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation.
    Meyers JD; Leszczynski J; Zaia JA; Flournoy N; Newton B; Snydman DR; Wright GG; Levin MJ; Thomas ED
    Ann Intern Med; 1983 Apr; 98(4):442-6. PubMed ID: 6301320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of transfusion-associated cytomegalovirus infection in very low-birthweight infants using frozen blood and donors seronegative for cytomegalovirus.
    Adler SP; Lawrence LT; Baggett J; Biro V; Sharp DE
    Transfusion; 1984; 24(4):333-5. PubMed ID: 6087517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia.
    Reed EC; Bowden RA; Dandliker PS; Gleaves CA; Meyers JD
    J Infect Dis; 1987 Oct; 156(4):641-5. PubMed ID: 3040870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.